Recently, a randomized phase II study of the efficacy of nanvuranlat as LAT1 inhibitor was reported for the patients with previously treated advanced biliary tract cancers, indicating that nanvuranlat significantly improved PFS compared to placebo group [27]. Here, SLC7A5 is linked to biliary tract neoplasm.